Tripping Up Defendants With Bootstrap Reasoning

Law360, New York (June 6, 2012, 1:14 PM EDT) -- Bartlett v. Mutual Pharmaceutical Co. Inc., a Stevens-Johnson/toxic epidermal necrolysis (SJS/TEN) generic drug case that produced a $21 million judgment upheld on appeal, gave us writer's block.

Upon first reading of the opinion, we thought Bartlett told the following story:

New Hampshire has adopted the controversial third aspect of the risk/utility doctrine so that plaintiff needed only to prove that the risk posed by the drug — sulindac, a nonsteroidal anti-inflammatory (NSAID) — outweighed its utility; it's often prescribed for the sort of shoulder pain suffered...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.